Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49
Key facts
- Who runs it
- Vaxcyte, Inc.
- Where
- Birmingham, Charlottesville, Chinle, Cincinnati, Gallup, Gulfport, Hollywood, Jupiter, Kansas City, Lenexa, Miami, New Orleans, Norman, North Charleston, Omaha, Philadelphia, Ridgeland, Riverside, Rochester, Salt Lake City, San Antonio, Shiprock, Southfield, Stockbridge, Sugar Land, Sunrise, Toms River, Valparaiso, Whiteriver, and Wichita, United StatesSee the 30 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 4,049 people enrolled
- Started
- 1 Dec 2025
- Ended
- 17 Sept 2026
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 31 valent pneumococcal conjugate vaccine
- PCV20
- PCV21
- Record updated
- 16 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Male or female ≥18 years of age (inclusive) at the time of randomization into the study
- Able and willing to complete the informed consent process
- Available for clinical follow-up through the last study visit
- In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator)
- Willing to have blood samples collected and used for research purposes
- Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process
- Female participants of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method
- Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary)
Who cannot take part
- Previous receipt of any licensed or investigational pneumococcal vaccine at any age
- Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study
- Receipt of any live vaccine within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1
- Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened)
- History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination
- Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study
- Is currently receiving immunosuppressive or immune-modifying therapy, including systemic corticosteroids (this includes ≥3 months of prednisone equivalent from 5 to <10 mg/day and ≥2 weeks of prednisone equivalent ≥10 mg/day)
- Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccination
- Current diagnosis of human immunodeficiency virus, Hepatitis B, or Hepatitis C
- Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency
- Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent
- Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws
- History of invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age
- History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation
- Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site
Where in United States
- Accel Research Site - Achieve - Birmingham - ERNBirmingham, United States
- Charlottesville Medical Research Center - Alcanza - HyperCoreCharlottesville, United States
- Center for Indigenous Health - Chinle - Johns Hopkins ProjectChinle, United States
- CTI Clinical Research CenterCincinnati, United States
- Center for Indigineous Health - Gallup - John Hopkins ProjectGallup, United States
- DelRicht Research, LLC - GulfportGulfport, United States
- Research Centers of America - Hollywood - CenExelHollywood, United States
- Health Awareness - Jupiter - ERNJupiter, United States
- Alliance for Multispecialty Research, LLC - Kansas CityKansas City, United States
- Johnson County Clin-Trials (JCCT)Lenexa, United States
- Suncoast Research Group, LLCMiami, United States
- DelRicht Clinical Research, LLC - New OrleansNew Orleans, United States
- Lynn Institute of NormanNorman, United States
- Coastal Carolina Research Center - Alcanza - HyperCoreNorth Charleston, United States
- Velocity Clinical ResearchOmaha, United States
- DM Clinical Research - PhiladelphiaPhiladelphia, United States
- SKY Integrative Medical Center/SKYCRNGRidgeland, United States
- Clinical Innovations Trials - Riverside - CenExelRiverside, United States
- Rochester Clinical Research - ATLAS - RochesterRochester, United States
- JBR Clinical Research - CenExel JBRSalt Lake City, United States
- Flourish Research San AntonioSan Antonio, United States
- Center for Indigineous Health - Shiprock - John Hopkins ProjectShiprock, United States
- Headlands Research - Detroit - HeadlandsSouthfield, United States
- Clinical Research Atlanta - HeadlandsStockbridge, United States
- DM Clinical Research - SugarlandSugar Land, United States
- Precision Clinical Research - SunriseSunrise, United States
- Advanced Memory Research Institute - CenExeToms River, United States
- Velocity Clinical Research - Valparaiso (Buynak Clinical Research)Valparaiso, United States
- Center for Indigineous Health - Whiteriver - John Hopkins ProjectWhiteriver, United States
- Alliance for Multispecialty Research, LLC - West WichitaWichita, United States
About the trial
What the trial wants to find out
The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.
The 5 groups in the trial
- Cohort 1 (VAX-31), participant ≥ 50 years of ageTreatment being tested
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Treatment: 31 valent pneumococcal conjugate vaccine
- Cohort 1 (PCV21), participant ≥ 50 years of ageExisting treatment, for comparison
Participants will receive a single dose of PCV21 (Capvaxive) administered via intramuscular injection at Day 1
Treatment: PCV21
- Cohort 1 (PCV20), participant ≥ 50 years of ageExisting treatment, for comparison
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Treatment: PCV20
- Cohort 2 (VAX-31), participant 18-49 years of ageTreatment being tested
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Treatment: 31 valent pneumococcal conjugate vaccine
- Cohort 2 (PCV20), participant 18-49 years of ageExisting treatment, for comparison
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Treatment: PCV20
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age
- Record updated
- 16 October 2026